Trak wins IMQ Igurco’s BIOK challenge to reduce the risks derived from dysphagia

Through BiOK!, Bizkaia’s innovation ecosystem, and within the framework of the Nagusi Intelligence Center, both of which are part of the Provincial Council   The company that won the challenge will pilot a telerehabilitation platform that, by applying a computer vision algorithm, assists and guides users in real time while they perform individualised exercises. Oropharyngeal…

ABYNTEK expands its portfolio of bioreagents with new partnerships

Abyntek strengthens its leadership in the distribution of the highest quality reagents for research, adding to its portfolio a wide variety of primary and secondary antibodies, proteins, ELISA kits and enzymes, joining its more than two million references to provide the best service to the scientific community. Recently, Abyntek has signed new agreements with global…

More than 20 Spanish hospitals collaborate with Mikrobiomik in the clinical development of the first biological drug based on gut microbiota

The Bizkaia-based company has launched its phase III clinical trial with the aim of becoming the first company in the world to market the first biological drug based on intestinal microbiota, in the indication of recurrence due to Clostridioides difficile (ICD). The biopharmaceutical company, based at the BIC Bizkaia bioincubator, is also supplying its investigational…

Biotalde analyses the risk of SARS-CoV-2 contagion on surfaces and air in non-sanitary spaces

Biotalde joins Aqualab (water consultancy and analysis) and the Germans Trias i Pujol University Hospital to analyse the risk of SARS-CoV-2 infection on surfaces and air in non-sanitary spaces. After a year of study, it has finally been possible to publish an article under the title “Bajo riesgo de contagio ambiental por SARS-CoV-2 en espacios”…

Seed Capital Bizkaia enters Mikrobiomik’s captital by investing in 3% of its shareholding

On 11 March, Seed Capital Bizkaia, in its aim to promote innovative business initiatives, invested in 3% of Mikrobiomik’s shares. “It is of the utmost interest to us to support companies like Mikrobiomik. They are clear example of the promotion of the business initiatives with an innovative vocation that we seek with our investment vehicle”,…

CIDETEC Surface Engineering establishes the basis for the generation of safe antibacterial and antiviral surfaces

With the rise of interest in protection against pathogens caused by the COVID-19 pandemic, there has been a significant increase in the demand for antibacterial and antiviral surfaces and coatings as one of the mechanisms to prevent their spread. CIDETEC Surface Engineering is leading the ‘Frontiers 2021’ project, promoting research in this field. The project…